Creating a new generation of small molecule protease inhibitors

2018 News Releases

Keyword Search
 
2018 | 2017 | 2016
DateTitle 
05/31/18KalVista Pharmaceuticals to Present at Jefferies Healthcare Conference
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--May 31, 2018-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present a corporate overview at the Jefferies Healthcare Conference on Friday, June 8, 2018, at 9:30 a.m. ET in New York, NY. A live webcast of the presentatio... 
Printer Friendly Version
05/29/18KalVista Pharmaceuticals Presents Data at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018
– KVD900 Data Accepted for Late Breaking Poster Session – CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--May 29, 2018-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced data from a poster presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018 in Mu... 
Printer Friendly Version
05/16/18KalVista Pharmaceuticals Recognizes HAE Day
– A Global Awareness Day for a Rare Life-Threatening Condition – CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--May 16, 2018-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced recognition of patient organizations from around the world holding a global awareness day for the condition her... 
Printer Friendly Version
05/02/18KalVista Pharmaceuticals Presents Data at The Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting
– Oral Plasma Kallikrein Inhibitor Blocks VEGF-induced Retinal Vascular Hyperpermeability – CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 2, 2018-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced data in support of the Company’s development activities in diabetic macular edema (DME) from an oral pr... 
Printer Friendly Version
04/18/18KalVista Pharmaceuticals to Present Data at The Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting
– Oral Plasma Kallikrein Inhibitor Data in a Preclinical Model of Retinal Edema to be Presented – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 18, 2018-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that data in support of KalVista’s ongoing development in diabetic macular edema (DME) has been... 
Printer Friendly Version
03/16/18KalVista Pharmaceuticals Reports Fiscal Third Quarter Results
– Enrollment Ongoing for a Phase 2 Clinical Trial of KVD001 in Diabetic Macular Edema (“DME”) and a Phase 1 Clinical Trial for the Second Candidate in the Oral Hereditary Angioedema (“HAE”) Portfolio – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 16, 2018-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today r... 
Printer Friendly Version
03/05/18KalVista Pharmaceuticals to Present at 30th Annual ROTH Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 5, 2018-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present a corporate overview at the ROTH Conference on Monday, March 12, 2018, at 2:30 p.m. PT in Orange County, CA. A live webcast of the presentation may be accessed on the Investors... 
Printer Friendly Version
01/05/18KalVista Pharmaceuticals Commences Two Clinical Trials
– Data Expected for Phase 2 Clinical Trial of KVD001 in Diabetic Macular Edema Patients in the Second Half of 2019 – – Second Oral Hereditary Angioedema Candidate Begins Phase 1 Clinical Trial – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 5, 2018-- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today an... 
Printer Friendly Version